Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment

Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment

The current standard of care for colorectal cancer (CRC) is a combination of chemotherapeutics, often supplemented with targeted biological drugs. An urgent need exists for improved drug efficacy and minimized side effects, especially at late‐stage disease. We employed the phenotypically driven ther...

Full description

Bibliographic Details
Main Authors: Marloes Zoetemelk, George M. Ramzy, Magdalena Rausch, Thibaud Koessler, Judy R. vanBeijnum, Andrea Weiss, Valentin Mieville, Sander R. Piersma, Richard R. deHaas, Céline Delucinge‐Vivier, Axel Andres, Christian Toso, Alexander A. Henneman, Simone Ragusa, Tatiana V. Petrova, Mylène Docquier, Thomas A. McKee, Connie R. Jimenez, Youssef Daali, Arjan W. Griffioen, Laura Rubbia‐Brandt, Pierre‐Yves Dietrich, Patrycja Nowak‐Sliwinska
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Molecular Oncology
Subjects:
colorectal carcinoma
combination treatment
drug–drug interactions
drug–target interactions
phosphoproteomics
synergy
Online Access:https://doi.org/10.1002/1878-0261.12797

Internet

https://doi.org/10.1002/1878-0261.12797

Similar Items